The Efficacy of Combination Therapy by Adalimumab with Methotrexate and of Monotherapy by Methotrexate for Children Suffering from Polyarticular Juvenile Idiopathic Arthritis
Background: The use of genetically engineered biological agents in patients with juvenile idiopathic arthritis (JIA) allows to achieve good results in treatment. However, their efficacy in patients refractory to basic antirheumatic drugs, requires further analysis.Objective: To study the efficacy an...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
"Paediatrician" Publishers LLC
2016-01-01
|
| Series: | Вопросы современной педиатрии |
| Subjects: | |
| Online Access: | https://vsp.spr-journal.ru/jour/article/view/1556 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849690856961867776 |
|---|---|
| author | V. A. Keltsev L. I. Grebyonkina Ye. D. Moiseeva |
| author_facet | V. A. Keltsev L. I. Grebyonkina Ye. D. Moiseeva |
| author_sort | V. A. Keltsev |
| collection | DOAJ |
| description | Background: The use of genetically engineered biological agents in patients with juvenile idiopathic arthritis (JIA) allows to achieve good results in treatment. However, their efficacy in patients refractory to basic antirheumatic drugs, requires further analysis.Objective: To study the efficacy and safety of the combination therapy by adalimumab with methotrexate and of the monotherapy by methotrexate in children with JIA.Methods: It was conducted a perspective (annual) comparative research with the analysis of the results of treating children with polyarticular seronegative JIA refractory to basic immunosuppressive therapy. The efficacy was assessed by ACRpedi criteria and by dynamics of values of cellular and humoral immunity indicators. Safety was determined by the number of adverse effects.Results: The combination therapy by methotrexate with adalimumab for children with JIA (n = 14) in a shorter time than the monotherapy by methotrexate (n = 17) induced arthritis remission. After 46 weeks of treatment, the remission of arthritis and the normalization of laboratory findings were reported in 6 (43%) patients treated by adalimumab with methotrexate, and in 3 (18%) children — methotrexate (p = 0.233); adverse effects — in 4 (29%) and 14 (82%) cases (p = 0.004), respectively. No serious adverse effects have been registered.Conclusion: The prescription of adalimumab in combination with methotrexate in children with JIA, refractory to basic immunosuppressive therapy, allows to achieve rapid remission of the disease while preserving the effect in a significant number of patients within 46 weeks of therapy. |
| format | Article |
| id | doaj-art-5921f56a55a347b187f32ef761d7fa3a |
| institution | DOAJ |
| issn | 1682-5527 1682-5535 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | "Paediatrician" Publishers LLC |
| record_format | Article |
| series | Вопросы современной педиатрии |
| spelling | doaj-art-5921f56a55a347b187f32ef761d7fa3a2025-08-20T03:21:12Zeng"Paediatrician" Publishers LLCВопросы современной педиатрии1682-55271682-55352016-01-0114667468010.15690/vsp.v14i6.14751547The Efficacy of Combination Therapy by Adalimumab with Methotrexate and of Monotherapy by Methotrexate for Children Suffering from Polyarticular Juvenile Idiopathic ArthritisV. A. Keltsev0L. I. Grebyonkina1Ye. D. Moiseeva2Samara State Medical University, Samara, Russian FederationSamara State Medical University, Samara, Russian FederationSamara State Medical University, Samara, Russian FederationBackground: The use of genetically engineered biological agents in patients with juvenile idiopathic arthritis (JIA) allows to achieve good results in treatment. However, their efficacy in patients refractory to basic antirheumatic drugs, requires further analysis.Objective: To study the efficacy and safety of the combination therapy by adalimumab with methotrexate and of the monotherapy by methotrexate in children with JIA.Methods: It was conducted a perspective (annual) comparative research with the analysis of the results of treating children with polyarticular seronegative JIA refractory to basic immunosuppressive therapy. The efficacy was assessed by ACRpedi criteria and by dynamics of values of cellular and humoral immunity indicators. Safety was determined by the number of adverse effects.Results: The combination therapy by methotrexate with adalimumab for children with JIA (n = 14) in a shorter time than the monotherapy by methotrexate (n = 17) induced arthritis remission. After 46 weeks of treatment, the remission of arthritis and the normalization of laboratory findings were reported in 6 (43%) patients treated by adalimumab with methotrexate, and in 3 (18%) children — methotrexate (p = 0.233); adverse effects — in 4 (29%) and 14 (82%) cases (p = 0.004), respectively. No serious adverse effects have been registered.Conclusion: The prescription of adalimumab in combination with methotrexate in children with JIA, refractory to basic immunosuppressive therapy, allows to achieve rapid remission of the disease while preserving the effect in a significant number of patients within 46 weeks of therapy.https://vsp.spr-journal.ru/jour/article/view/1556childrenjuvenile idiopathic arthritiscytokinestreatmentadalimumabmethotrexate |
| spellingShingle | V. A. Keltsev L. I. Grebyonkina Ye. D. Moiseeva The Efficacy of Combination Therapy by Adalimumab with Methotrexate and of Monotherapy by Methotrexate for Children Suffering from Polyarticular Juvenile Idiopathic Arthritis Вопросы современной педиатрии children juvenile idiopathic arthritis cytokines treatment adalimumab methotrexate |
| title | The Efficacy of Combination Therapy by Adalimumab with Methotrexate and of Monotherapy by Methotrexate for Children Suffering from Polyarticular Juvenile Idiopathic Arthritis |
| title_full | The Efficacy of Combination Therapy by Adalimumab with Methotrexate and of Monotherapy by Methotrexate for Children Suffering from Polyarticular Juvenile Idiopathic Arthritis |
| title_fullStr | The Efficacy of Combination Therapy by Adalimumab with Methotrexate and of Monotherapy by Methotrexate for Children Suffering from Polyarticular Juvenile Idiopathic Arthritis |
| title_full_unstemmed | The Efficacy of Combination Therapy by Adalimumab with Methotrexate and of Monotherapy by Methotrexate for Children Suffering from Polyarticular Juvenile Idiopathic Arthritis |
| title_short | The Efficacy of Combination Therapy by Adalimumab with Methotrexate and of Monotherapy by Methotrexate for Children Suffering from Polyarticular Juvenile Idiopathic Arthritis |
| title_sort | efficacy of combination therapy by adalimumab with methotrexate and of monotherapy by methotrexate for children suffering from polyarticular juvenile idiopathic arthritis |
| topic | children juvenile idiopathic arthritis cytokines treatment adalimumab methotrexate |
| url | https://vsp.spr-journal.ru/jour/article/view/1556 |
| work_keys_str_mv | AT vakeltsev theefficacyofcombinationtherapybyadalimumabwithmethotrexateandofmonotherapybymethotrexateforchildrensufferingfrompolyarticularjuvenileidiopathicarthritis AT ligrebyonkina theefficacyofcombinationtherapybyadalimumabwithmethotrexateandofmonotherapybymethotrexateforchildrensufferingfrompolyarticularjuvenileidiopathicarthritis AT yedmoiseeva theefficacyofcombinationtherapybyadalimumabwithmethotrexateandofmonotherapybymethotrexateforchildrensufferingfrompolyarticularjuvenileidiopathicarthritis AT vakeltsev efficacyofcombinationtherapybyadalimumabwithmethotrexateandofmonotherapybymethotrexateforchildrensufferingfrompolyarticularjuvenileidiopathicarthritis AT ligrebyonkina efficacyofcombinationtherapybyadalimumabwithmethotrexateandofmonotherapybymethotrexateforchildrensufferingfrompolyarticularjuvenileidiopathicarthritis AT yedmoiseeva efficacyofcombinationtherapybyadalimumabwithmethotrexateandofmonotherapybymethotrexateforchildrensufferingfrompolyarticularjuvenileidiopathicarthritis |